Treatment with omalizumab may reduce exacerbations of asthma in patients in several different airway reversibility subgroups.
Patients who began biologic treatment for asthma tended to have more progressive worsening of disease in the previous 2 years
Benralizumab does not induce changes in weight or blood pressure when administered for up to 1 year in patients with severe asthma.
The addition of formoterol to mometasone furoate was well tolerated and provided significant improvement in lung function in children compared with mometasone furoate alone.
In patients with asthma, benralizumab is associated with substantial improvements in total scores on the St. George’s Respiratory Questionnaire.
Response to omalizumab was similar regardless of the number and type of sensitizing allergens in patients with allergic asthma.